Ketamine Update with Brandon Kitay, M.D.

Psychiatry & Psychotherapy Podcast

David J Puder

Science, Health & Fitness, Medicine

4.8 • 1.3K Ratings

🗓️ 27 January 2022

⏱️ 83 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Esketamine is the first non-monoaminergic based medication which is FDA approved and indicated for treatment refractory depression. A longer duration of undertreated depression is associated with poor longitudinal functional outcomes. Instead of cycling patients through monoaminergic antidepressant trials and cognitive behavioral therapy approaches, according to Dr. Kitay, providers should consider treatments like esketamine much sooner in the treatment course.

Link to full blog

Link to Resource Library.

Transcript

Click on a timestamp to play from that location

0:00.0	Hello and welcome to the Psychiatry and Psychothermic Podcast.
0:12.2	I'm here to talk about getting rid of burnout, increasing job satisfaction, and feeling
0:16.6	like an expert in what you do.
0:18.6	One thing that created a lot of burnout and angst for me was trying to get continued
0:21.7	medical education right at the last minute.
0:24.2	So why not join the CME membership and do CME while listening to this podcast?
0:28.6	Go to Psychiatrypodcast.com, sign up, sign in, take the test, and the certification
0:32.5	is emailed to you in seconds.
0:34.8	All right, welcome back to the podcast.
0:37.0	I am here today with Dr. Brandon Kite.
0:41.9	He is a MD-PhD at Emory, who was previously at Yale, who did some of the initial ketamine
0:51.5	test ketamine drug trials.
0:54.2	And so it looked like Emory kind of recruited you to take over their interventional Psychiatry
0:59.4	Department there or part of it.
1:01.3	Can you tell me a little bit about that story and what's going on with you lately?
1:04.6	Yeah, yeah, sure.
1:05.8	So let me start also just with the few disclosures because our discussion today, yeah, let's
1:12.0	do that.
1:13.0	Yeah.
1:14.0	Talk about some novel therapies.
1:15.9	So I have received some salary support historically from Janssen Pharmaceuticals, where
1:22.1	the makers and proprietors of the S ketamine spravado.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from David J Puder, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of David J Puder and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.